ChenCheng

Tel:+86-551-65595249
Phone: 18788832059

E-mail: chencheng@hmfl.ac.cn

Work and study experience

2016/09-present, PhD Candidate, University of Science and Technology of China
2013/07–2016/08, Research Assistant, High Magnetic Field Laboratory, Chinese Academy of Sciences
2010/09–2013/06, Institute of Clinical Pharmacology, Anhui Medical University, Master

Pubications

  1. Cheng Chen#, Jing-mo Yang#, Tingting Hu, Tingjuan Xu, Weiping, Xu*, Wei Wei*. Elevated dopamine D2 receptor in prefrontal cortex of CUMS rats is associated with downregulated cAMP-independent signaling pathway.  Can. J. Physiol. Pharmacol. 2013, 91(9): 750-8.
  2. Cheng Chen, Jingmo Yang, Tingting Hu, Tingjuan Xu, Guang Yan, Shilian Hu, Wei Wei, Weiping Xu*. Prognostic role of human epidermal growth factor receptor in gastric cancer: A meta-analysis. Arch. Med. Res., 2013 44(5): 380-9.
  3. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang#, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Cai-Hong Yun*, Jing Liu*. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med. Chem. 2017, DOI: 10.1016/j.ejmech.2017.03.001.
  4. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Wang Li, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu *. Characterization of Selective and Potent PI3Kδ Inhibitor (PI3KD-IN-015) for B-Cell Malignances. Oncotarget 2016, 7(22): 32641-51.
  5. Aoli Wang#, Hong Wu#, Cheng Chen#, Chen Hu#, Qi Ziping Ziping Qi, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Wang Li, Richard M. Stone, Ilene A. Galinksy, James D. Griffin4, Shanchun Zhang, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget 2016, 7(20): 29131-42.
  6. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen#, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, Qingsong Liu *. Discovery of N-(3-((1-isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl) benzamide (CHMFL-KIT-110) as a Selective, Potent and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-79.
  7. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#,Cheng Chen#, Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*,Qingsong Liu*. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR(T790M) mutant NSCLC Cells. Oncotarget 2015, 6(31): 31313-22.
  8. Hong Wu#， Qiong Huang#， Ziping Qi#， Yongfei Chen#, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports , 2017, DOI: 10.1038/s41598-017-00482-4.
  9. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, and Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01907.
  10. Xiaofei Liang, Fengchao Lv, Beilei Wang, Kailin Yu, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxy benzamido) phenyl) -4-(methylamino) pyrimidine-5-carboxamide(CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, Jan 31.DOI: 10.1021/acs.jmedchem.6b01413.
  11. Qiang Wang, Feiyang Liu, Beilei Wang, Fengming Zou, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-89.
  12. Wu Hong, Hu Chen, Wang Aoli, E L Weisberg, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin, Liu Jing*, Liu Qingsong*. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2016, 30(3): 754-7.
  13. Hong Wu, Chen Hu, Aoli Wang, Ellen L. Weisberg, Yongfei Chen, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Qingsong Liu*. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.Leukemia 2016, 30(1): 173-81.
  14. Binhua Li, Aoli Wang, Juan Liu, Ziping Qi, Xiaochuan Liu, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. J. Med. Chem. 2016, 59(18): 8456-72. 
  15. Feiyang Liu, Beilei Wang, Qiang Wang, Ziping Qi, Cheng Chen, Lu-Lu Kong, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun, Zhimin Zhai, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).Oncotarget 2016, 7(29): 45562-74.
  16. Hong Wu, Aoli Wang, Ziping Qi, Xixiang Li, Cheng Chen, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016, (10): 2112-16.
  17. Aoli Wang, Xiao-E Yan, Hong Wu, Wenchao Wang, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*,Cai-Hong Yun*, Qingsong Liu*. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 2016, 7(43): 69760-9.
  18. Xiaochuan Liu, Aoli Wang, Xiaofei Liang, Juanjuan Liu, Fengming Zou, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wan, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Xin Zhang*, Jing Liu*, Qingsong Liu*. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7(33): 53515-25.
  19. Xixiang Li, Aoli Wang, Kailin Yu, Ziping Qi, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58(24): 9625-38.

参与申请中国专利

  1. 一种新型的PDGFR激酶抑制剂及其用途。发明人： 刘青松，刘静， 王强， 刘飞扬，亓爽，王蓓蕾，王文超，王傲莉，王伟，陈程，刘晓川，蒋宗儒，胡祯全，任涛，王黎。专利受理号：201610811854.7
  2. FLT3激酶的新型抑制剂及其用途。发明人： 刘青松， 刘静， 李希祥， 王傲莉， 齐紫平，吴宏， 吴佳昕，王文超，胡晨，陈程， 王黎，王蓓蕾。专利受理号：201610409235.5
  3. 一种选择性的C-KIT激酶抑制剂。发明人： 刘青松，刘静，王强，王蓓蕾，刘飞扬，亓爽，齐紫平，邹凤鸣，陈程，王文超，胡晨，刘晓川，王伟，王傲莉，王黎，胡祯全，任涛。专利受理号：2201610210424.X
  4. 一种新型布鲁顿酪氨酸激酶不可逆抑制剂。发明人：刘静， 刘青松， 梁前茅，陈永飞，陈程，王傲莉，吴宏，余凯琳，王伟，胡晨，王文超，亓爽，王蓓蕾，王黎。专利受理号：201610084082.1
  5. 一类新型的 EGFR 野生型和突变型的激酶抑制剂。发明人： 刘青松， 刘静， 李希祥， 王傲莉，吴宏，余凯琳，胡晨，王文超，陈程，邹凤鸣，齐紫平，王黎，王蓓蕾。专利受理号：201511030721.8
  6. 曲西立滨（Triciribine）及相关代谢产物对FLT3突变的急性白血病的应用。发明人：刘青松， 刘静， 王傲莉， 吴宏， 王文超，陈程，胡晨，李滨华，齐紫平，余凯琳，王黎。专利受理号：2201510665488.4
  7. 一类新型的FLT3激酶抑制剂及其用途。发明人：刘青松， 刘静， 李滨华，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，余凯琳，王蓓蕾，王黎。专利受理号：2201510608850.4
  8. FLT3激酶的新型抑制剂及其用途。发明人：刘青松，刘静，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾 。专利受理号：201510547224.9
  9. A674563在携带FLT3突变型基因的急性白血病中的新用途 。发明人：刘青松， 刘静， 王傲莉，吴宏，陈程，胡晨，王文超，刘晓川，余凯琳，赵铮，吴佳昕，刘娟，王黎，王蓓蕾 。专利受理号：201510262944.0
  10. 一种新型的BCR-ABL激酶抑制剂 。发明人：刘静，刘青松，梁小飞，王蓓蕾，王傲莉，刘晓川，陈程，齐紫平，王文超，赵铮，王黎 。专利受理号：201510172534.7
  11. FLT3激酶的新型抑制剂及其用途。发明人：刘静，刘青松，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾 。专利受理号：201510028177.7
  12. 一种新型的 PI3K 激酶抑制剂 。发明人：刘青松，刘静，张欣，梁小飞，刘晓川，刘娟娟，陈程，赵铮，王傲莉，王文超，吴宏，王蓓蕾，王黎 。专利受理号：201410821908.9
  13. 一种新型结构的激酶抑制剂 。发明人：刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎 。专利受理号：201410757626.7
  14. 依鲁替尼对FLT3-ITD突变的急性白血病的应用 。发明人：刘青松，刘静，吴宏，胡晨，王傲莉，王文超，陈程，李希祥，赵铮，王黎，王蓓蕾 。专利受理号：201410598948.1
  15. 依鲁替尼的新用途 。发明人：刘青松，刘静，王蓓蕾，王傲莉，吴宏，胡晨，王文超，陈程，王黎，李希祥。专利受理号：201410258423.3
  16. 一种新型Bruton酪氨酸激酶抑制剂 。发明人：刘青松，刘静，陈永飞，吴宏，王傲莉，王蓓蕾，胡晨，王文超，陈程。专利受理号：201410280931.1

参与申请PCT专利

  1. "NEW BRUTON'S TYROSINE KINASE INHIBITOR",Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2016,EP) 15809083.7.
  2. "NEW BRUTON'S TYROSINE KINASE INHIBITOR",Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2016,US) 15/320,120.
  3. "New class of Wild type/Mutant EGFR inhibitors",Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli;Wu Hong;Yu Kailin;Hu Chen;Wang Wenchao; Chen Cheng;Zou Fengming;Qi Ziping;Wang Li; Wang Beilei; (2016). PCT/CN2016/112322.
  4. "New class of Wild type/Mutant EGFR inhibitors",Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli;Wu Hong;Yu Kailin;Hu Chen;Wang Wenchao; Chen Cheng;Zou Fengming;Qi Ziping;Wang Li; Wang Beilei; (2016).PCT/CN2016/112322.
  5. "A new type of Bruton's tyrosine kinase irreversible inhibitors", Liu Jing;Liu, Qingsong; Liang Qianmao;Chen Yongfei; Chen Cheng;Wang Aoli; Wu Hong; Yu Kailin;Wang Wei;Hu Chen;Wang Wenchao; Qi Shuang; Wang Beilei; Wang Li. (2016). PCT/CN2016/111442.
  6. "Triciribine and its metabolite is sensitive to FLT3-ITD dependent AML". Liu, Qingsong; Liu Jing; Wang Aoli; Wu Hong; Wang Wenchao; Chen Cheng; Hu Chen; Li Binhua; Ziping Qi; Yu Kailin; Wang Li. (2015). PCT/CN2015/092600.
  7. "A new type of FLT3 kinase inhibitors and its application". Liu, Qingsong; Liu Jing;Li Binhua;Wang Aoli; Wu Hong; Chen Cheng; Wang Wenchao; Hu Chen; Zhao Zheng; Yu Kailin;Wang Beilei; Wang Li. (2015). PCT/CN2015/090306.
  8. "FLT3 kinase new inhibitors and its application". Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015). PCT/CN2015/086318.
  9. "A674563 is sensitive to FLT3-ITD dependent AML". Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong; Chen Cheng; Hu Chen; Wang Wenchao; Liu Xiaochuan; Yu Kailin; Zhao Zheng; Wu Jiaxin; Liu Juan; Wang Li; Wang Beilei. (2015). PCT/CN2015/083717
  10. "New class of BCR-ABL's kinase inhibitors". Liu Jing; Liu, Qingsong; Liang Xiaofei; Wang Beilei; Wang Aoli; Liu Xiaochuan; Chen Cheng; Qi Ziping; Wang Wenchao; Zhao Zheng; Wang Li. (2015). PCT/CN2015/081220
  11. "New class of PI3K's kinase inhibitors". Liu, Qingsong; Liu Jing; Zhang Xin; Liang Xiaofei; Liu Xiaochuan; Liu Juanjuan; Chen Cheng; Zhao Zheng; Wang Aoli; Wang Wenchao; Wu Hong; Wang Beilei; Wang Li. (2015). PCT/CN2015/081240
  12. "New application of Ibrutinib". Liu, Qingsong; Liu Jing; Wang Beilei; Wang Aoli; Wu Hong; Hu Chen; Wang Wenchao; Chen Cheng; Wang Li; Li Xixiang; Li Xiaoxiang; Xu Ziao.(2015). PCT/CN2015/081051
  13. "New class of Bruton's tyrosine kinase inhibitors". Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2015). PCT/CN2015/071594
  14. "Ibrutinib is sensitive to FLT3-ITD dependent AML", Liu, Qingsong; Liu Jing; Wu Hong; Hu Chen; Wang Aoli; Wang Wenchao; Chen Cheng; Li Xixiang; Zhao Zheng; Wang Li; Wang Beilei.(2014). PCT/CN2014/091375.